We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+19.81%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.35B
AUM Growth
+$99.6M
Cap. Flow
-$51.8M
Cap. Flow %
-3.83%
Top 10 Hldgs %
51.22%
Holding
199
New
40
Increased
30
Reduced
31
Closed
45

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$43.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
3
BAX icon
Baxter International
BAX
+$15.5M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$13.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$11.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$22.7M
2
RLYP
RELYPSA INC COM
RLYP
+$18.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$17.6M
4
CEMP
Cempra, Inc.
CEMP
+$16.2M
5
SHPG
Shire pic
SHPG
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 86%
2 Consumer Discretionary 0.08%
3 Financials 0.04%
4 Consumer Staples 0.02%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
26
DELISTED
Acceleron Pharma
XLRN
$13.5M 1%
276,036
– –
CTMX icon
27
CytomX Therapeutics
CTMX
$690M
$13.4M 0.99%
+642,047
New +$10.2M
RGNX icon
28
Regenxbio
RGNX
$616M
$12.9M 0.96%
779,213
– –
CDTX
29
DELISTED
Cidara Therapeutics
CDTX
$12.7M 0.94%
37,143
– –
PFNX
30
DELISTED
Pfenex Inc.
PFNX
$11.9M 0.88%
960,877
-10,166
-1% -$150K
EGRX
31
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$11.8M 0.87%
133,145
+10,101
+8% +$798K
DBVT
32
DBV Technologies
DBVT
$813M
$11.1M 0.82%
30,672
– –
BPMC
33
DELISTED
Blueprint Medicines
BPMC
$10.7M 0.79%
404,404
– –
SNDA icon
34
Sonida Senior Living
SNDA
$1.93B
$10.1M 0.75%
32,247
-4,660
-13% -$1.55M
SIOX
35
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$9.65M 0.71%
66,875
+15,625
+30% +$2.03M
ASRT
36
DELISTED
Assertio
ASRT
$9.06M 0.67%
+8,333
New +$9.37M
ACAD icon
37
Acadia Pharmaceuticals
ACAD
$4.51B
$8.74M 0.65%
245,240
-50,000
-17% -$1.76M
BLCM
38
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$8.54M 0.63%
42,119
-10,000
-19% -$1.79M
ALDX icon
39
Aldeyra Therapeutics
ALDX
$97.1M
$8.41M 0.62%
1,240,458
+283,265
+30% +$1.9M
AMGN icon
40
Amgen
AMGN
$209B
$8.12M 0.6%
50,000
+48,720
+3,806% +$7.66M
VBIV
41
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$7.96M 0.59%
108,679
– –
CASC
42
DELISTED
Cascadian Therapeutics, Inc.
CASC
$7.58M 0.56%
569,020
-22,130
-4% -$381K
MYOK
43
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$7.37M 0.55%
+502,903
New +$6.15M
NEPT
44
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$7.17M 0.53%
4,786
– –
ARCT icon
45
Arcturus Therapeutics
ARCT
$165M
$6.46M 0.48%
+146,896
New +$6.61M
AFMD
46
DELISTED
Affimed
AFMD
$6.19M 0.46%
86,882
+20
+0% +$1.36K
ASMB icon
47
Assembly Biosciences
ASMB
$498M
$5.97M 0.44%
66,250
– –
ABEO icon
48
Abeona Therapeutics
ABEO
$355M
$5.92M 0.44%
70,515
– –
ARDX icon
49
Ardelyx
ARDX
$1.24B
$5.72M 0.42%
315,955
– –
OTIC
50
DELISTED
Otonomy, Inc.
OTIC
$5.72M 0.42%
205,986
+20,618
+11% +$513K
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Perceptive Advisors held 199 positions worth $1.35B, up 8% from $1.25B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $51.8M in Q4 2015, closing 45 positions and reducing 31 holdings. Its most notable exit was RELYPSA INC COM, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 78% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Perceptive Advisors opened a new position in Allergan plc worth $45.3M.

  • Perceptive Advisors's largest Q4 2015 buy was Allergan plc: 145,000 shares worth $45.3M.
  • Perceptive Advisors added most to Teva Pharmaceuticals in Q4 2015, an estimated $19.8M increase.
  • Perceptive Advisors's biggest Q4 2015 reduction was Neurocrine Biosciences, cutting an estimated $22.7M.
  • Perceptive Advisors fully exited RELYPSA INC COM in Q4 2015, selling an estimated $18.3M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $1.35B portfolio in Q4 2015.
  • Perceptive Advisors opened 40 new positions and closed 45 in Q4 2015.
  • Perceptive Advisors's portfolio value rose 8% quarter-over-quarter to $1.35B.

Based on Perceptive Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.